

DATE MAILED: October 15, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rasmus B. JENSEN, et al.

Application No. 10/724,271

Filed: November 26, 2003

For: OPTICAL INFORMATION

CARRIER COMPRISING

IMMOBILIZED

PROTEORHODOPSIN

Art Unit: 3761

Examiner: Not Yet Assigned

Confirmation No. 1257

Attorney Docket: 02716.0011.NPUS00

Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
 - □ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - □ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - c. Before the mailing date of a first Office Action on the merits;
 - □ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- □ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or

□ b.	I hereby state that no item of information in this Information Disclo	sure			
	Statement was cited in a communication from a foreign pa	atent			
	office in a counterpart foreign application, and, to my knowl	edge			
	after making reasonable inquiry, no item of information conta	iined			
	in this Information Disclosure Statement was known to	any			
	individual designated in 37 C.F.R. § 1.56(c) more than to	three			
	months prior to the filing of this Information Disclosure Statement.				
	37 C.F.R. § 1.97(e)(2), or				
□ с.	Attached is our Check No. in the amount of \$	in			

- payment of the fee under 37 C.F.R. § 1.17(p).
- □ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a

 foreign patent office in a counterpart foreign application not more
 than three months prior to the filing of this Information Disclosure

 Statement. 37 C.F.R. § 1.97(e)(1), or
 - □ b. I hereby state that no item of information in this Information Disclosure

 Statement was cited in a communication from a foreign patent
 office in a counterpart foreign application, and, to my knowledge
 after making reasonable inquiry, no item of information contained
 in this Information Disclosure Statement was known to any
 individual designated in 37 C.F.R. § 1.56(c) more than three
 months prior to the filing of this Information Disclosure Statement.

 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.

□ 5.	The d	ocument(s) was/were cited in	n a corresponding foreign application. An			
		English language version of	the foreign search report is attached for the			
		Examiner's information.				
□ 6.	A cone	cise explanation of the relevan	nce of the non-English language document(s)			
		appears below:				
□ 7.	The E	xaminer's attention is directed	to co-pending U.S. Patent Application No.			
		, filed	, which is directed to related technical subject			
		matter. The identification of	of this U.S. Patent Application is not to be			
		construed as a waiver of s	ecrecy as to that application now or upon			
		issuance of the present ap	oplication as a patent. The Examiner is			
		respectfully requested to con	nsider the cited application and the art cited			
		therein during examination.				
□ 8.	Copies	s of the documents were cited	by or submitted to the Office in Application			
		No, filed	, which is relied upon for an earlier			
	filing date under 35 U.S.C. § 120. Thus, copies of these documents ar					
	not attached. 37 C.F.R. § 1.98(d).					
	It is respectfully requested that the Examiner initial and return a copy of the					
enclose	ed PTO	-1449, and to indicate in the o	fficial file wrapper of this patent application			
that the	e docun	nents have been considered.				
	The U	S. Patent and Trademark Offic	ce is hereby authorized to charge any fee			
deficie	ncy, or	credit any overpayment, to ou	r Deposit Account No. 08-3038 referencing			
docket	numbe	r 02716.0011.NPUS00 .				
			Respectfully submitted,			
		`	Respectivity submitted,			
Date:	Octobe	r 15, 2004	Chil I			
			Viola T. Kung (Reg. No. 41,131)			

HOWREY SIMON ARNOLD & WHITE, LLP 301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
(650) 463-8181



INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO. SERIAL NO. 02716.0011.NPUS00 10/724,271

APPLICANTS: Rasmus B. Jensen, et al.

FILING DATE GROUP: 3761

INITIAL MM-YYYY		ING ATE					
EX'R PATENT NO. DATE NAME CLASS SUI							
INITIAL MM-YYYY							
1. 5,290,699 03/01/1994 Oesterhelt, et al.							
2. 5,346,789 09/13/1994 Lewis, et al.							
3. 5,374,492 12/20/1994 Hampp, <i>et al.</i>							
4. 5,470,690 11/28/1995 Lewis, <i>et al.</i>							
5. 6,274,279 08/14/2001 Hampp, <i>et al.</i>							
FOREIGN PATENT DOCUMENTS		<u> </u>					
	IBCLASS TRANS	TRANSLATION					
INITIAL MM-YYYY	YES	NO					
6. WO 01/83701 A2 11/08/2001 PCT							
7. WO 03/002351 A1 01/09/2003 PCT	Х						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages	s, Etc.)						
EX'R DOCUMENT INITIAL							
8. Bejà, <i>et al.</i> , "Bacterial Rhodopsin: Evidence for a New Type of Phototrophy in 289, 1902-6 (2000)	Bejà, et al., "Bacterial Rhodopsin: Evidence for a New Type of Phototrophy in Sea," in Science, 289, 1902-6 (2000)						
9. Bejà, <i>et al.</i> , "Proteorhodopsin Phototrophy in Ocean," <i>in Nature</i> , <u>411</u> , 786-9 (2	Bejà, et al., "Proteorhodopsin Phototrophy in Ocean," in Nature, 411, 786-9 (2001)						
Cullin, et al., "Optical properties of Triton X-100 treated purple membranes er films," Supramolecular Sci., 2(1): 25-32 (1995)	Cullin, et al., "Optical properties of Triton X-100 treated purple membranes embedded in gelatin films," Supramolecular Sci., 2(1): 25-32 (1995)						
Dioumaev, et al., "Proton Transfers in the Photochemical Reaction Cycle of F Biochem. 41, 5348-58 (2002)	Dioumaev, et al., "Proton Transfers in the Photochemical Reaction Cycle of Proteorhodopsin," Biochem. 41, 5348-58 (2002)						
Dioumaev, et al., "Proton Transport by Proteorhodopsin Requires that Renita Cunterion Asp-97 Be Anionic," Am. Chem. Society. 42, 6582-7 (2003)	Dioumaev, et al., "Proton Transport by Proteorhodopsin Requires that Renital Schiff Base Cunterion Asp-97 Be Anionic," Am. Chem. Society. 42, 6582-7 (2003)						
Downie, <i>et al.</i> , "Measurements of holographic properties of bacteriorhodopsir <i>Optics</i> , <u>35(29)</u> : 5780-9 (1996)	Downie, et al., "Measurements of holographic properties of bacteriorhodopsin films," Applied Optics, 35(29): 5780-9 (1996)						
Friedrich, et al., "Proteorhodopsin is a Light-driven Proton Pump with Variable Biol., 321, 821-38 (2002)	Friedrich, et al., "Proteorhodopsin is a Light-driven Proton Pump with Variable Vectoriality," J. Mol. Biol., 321, 821-38 (2002)						

Page 2 of 2

XAMINI	ER: DATE CONSIDERED: R: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line		
24.	Váró, et al., "Characterization of Photochemical Reaction Cycle of Proteorhodopsin," J. Biophysical, 84, 1202-7 (2003)		
23.	Sabehi, et al., "Novel Proteorhodopsin variants from Mediterranean and Red Seas," <i>Environmental Microbiol.</i> , <u>5(10)</u> : 842-9 (2003)		
22.	Man, et al., "Diversification and spectral tuning in marine proteorhodopsins," J. EMBO, 22, 1725-31 (2003)		
21.	Krebs, <i>et al.</i> , "Resonance Raman Characterization of Proteorhodopsin's Chromophore Environment," J. <i>Phys. Chem. B G</i> , <u>107</u> , 7877-83 (2003)		
20.	Krebs, et al., "Detection of fast light-activated H+ release and M intermediate formation from Proteorphodopsin," BioMed. Central Physiol., 2, 1-8 (2002)		
19.	Juchem, et al., "Reflection-type polarization holograms in bacteriorhodopsin films for low-light recording," Optical Society of Amer., 26(21): 1702-04 (2001)		
18.	Hampp, "Printing Inks Containing the Photochromic Protein Bacteriorhodopsin," <i>Proc. SPIE</i> , <u>3979</u> , 118-25 (2000)		
17.	Hampp, "Bacteriorhodopsin: mutating a biomaterial into an optoelectronic material," <i>Appl. Microbiol. Biotechnol.</i> ," <u>53</u> , 633-9 (2000)		
16.	Hampp, "Bacteriorhodopsin as a Photochromic Retinal Protein for Optical Memories," <i>Amer. Chem. Society</i> , <u>100</u> , 1755-76 (2000)		
15.	Gill, et al., "Encapsulation of Biologicals within Silicate, Siloxane, and Hybrid Sol – Gel Polymers: An Efficient and Generic Approach," <i>J. Amer. Chem. Society</i> , 120, 8587-98 (1998)		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).